Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 887 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Estimate of the Global Economic Cost of the Most Prevalent Cancers... March 13, 2023 What to Expect During a Skin Cancer Screening May 31, 2022 Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or... March 3, 2025 Some People with Rectal Cancer Can Skip Radiation Before Surgery July 19, 2023 Load more HOT NEWS Significant Benefits of Nivolumab Plus Cabozantinib Over Sunitinib in Previously Untreated... Efficacy of a Bispecific Monoclonal Antibody Glofitamab for Relapsed or Refractory... How Receiving My Own Cancer Diagnosis Changed My Perspective on Caring... Sacituzumab Govitecan Demonstrates Overall Survival Benefit Over Chemotherapy in Patients with...
